Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data.

Prostate Cancer and Prostatic Diseases
Chang Wook JeongCheol Kwak

Abstract

Enzalutamide can significantly prolong the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is a paucity of evidence on continuing androgen-deprivation therapy (ADT) for mCRPC. Here, we analyzed the effect of concomitant ADT during enzalutamide treatment in men with mCRPC following chemotherapy. We retrospectively reviewed the medical records of 232 patients with mCRPC who received oral enzalutamide (160 mg per day) following chemotherapy at 9 tertiary centers in Korea between 2014 and 2016. The primary endpoint was overall survival, while secondary endpoints included time to prostate-specific antigen (PSA) progression and radiographic progression-free survival. The median age of the patients was 71 years (interquartile range, 64-75 years). The proportion of patients in a grade group ≥4 was 77.6%. The rate of concomitant ADT was 29.3%, and the all-cause mortality rate was 27.1% (n = 63). Median overall survival, time to PSA progression, and radiographic progression-free survival were 24.0, 8.0, and 10.0 months, respectively. Notably, concomitant ADT showed a significant association with longer overall survival (median duration not reached vs. 18.2 months; p = 0.008). After adjust...Continue Reading

References

Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C D TaylorD L Trump
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Jul 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gerhardt AttardJohann S de Bono
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Mar 20, 2012·European Urology·Melissa M CenterFreddie Bray
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Mar 13, 2015·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Kyu-Won JungKang Hyun Lee
Dec 17, 2015·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Lindsey A TorreAhmedin Jemal
Feb 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group 3
Jun 6, 2017·The New England Journal of Medicine·Karim FizaziUNKNOWN LATITUDE Investigators
Jun 6, 2017·The New England Journal of Medicine·Nicholas D JamesUNKNOWN STAMPEDE Investigators

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear translocation

Clinical Trials Mentioned

NCT01487902
NCT01224405

Software Mentioned

Research Electronic Data Capture ( REDCap )
REDCap
SPARE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.